Pete From the AS agreement.

(i) Development Milestones
For the UP/UPS Indication:

(1) US$ 1 million, upon Commencement of the First Phase III Clinical Trial; and

(2) US$ 1 million, upon the first filing of the Marketing Approval application to the US Regulatory Authority (“FDA”) or the EU Regulatory Authority (“EMA”), as applicable, without any duplication;



(ii) Regulatory Milestones
For the UP/UPS Indication:
(1) US$ 3 million, upon obtainment of the Marketing Approval from FDA; and



(2) US$ 1 million, upon obtainment of the Marketing Approval from EMA.



(iii) Sales Milestones






First achievement of US$ 100 million US$ 3 million



First achievement of US$ 200 million US$ 6 million



First achievement of US$ 300 million US$ 9 million